<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03741179</url>
  </required_header>
  <id_info>
    <org_study_id>STOPPRE</org_study_id>
    <secondary_id>2018-000811-26</secondary_id>
    <nct_id>NCT03741179</nct_id>
  </id_info>
  <brief_title>Detection of False Positives From First-trimester Preeclampsia Screening (StopPRE) at the Second-trimester of Pregnancy</brief_title>
  <acronym>StopPRE</acronym>
  <official_title>A Phase III, Multicentric, Randomized, Open-label, Parallel-group Clinical Trial to Detect False Positives From First-trimester Preeclampsia Screening (StopPRE) at the Second-trimester of Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pregnant women at a higher risk for pre-eclampsia (PE) should be offered preventive daily&#xD;
      treatment with acetylsalicylic acid (ASA) started before 16 weeks of gestation. To select&#xD;
      patients at higher risk for PE, multiparametric assessment combining maternal history,&#xD;
      biochemical factors and biophysical factors should be used during the first trimester of&#xD;
      pregnancy. Multiparametric risk assessments have a detection rate for early-onset PE around&#xD;
      80% at a false positive rate of 10%. Owing to the low prevalence of early-onset and preterm&#xD;
      PE, more than 90% of patients considered at high risk, at the first-trimester screening, will&#xD;
      not eventually develop PE. Thus, ASA treatment would be innecessary and could be safely&#xD;
      discontinued in these patients.&#xD;
&#xD;
      The sFlt-1 to PlGF ratio has a high negative predictive value for PE during the second and&#xD;
      third trimester of pregnancy. Thus, it could be used to detect false-positive patients from&#xD;
      the first-trimester screening.&#xD;
&#xD;
      This is a multicentric, randomized, open, parallel, controlled, phase III trial, where 1,080&#xD;
      patients under treatment with ASA for being at high risk for preeclampsia from the&#xD;
      first-trimester screening, will be candidates to participate. Patients with a sFlt-1/PlGF&#xD;
      &lt;38, from 24 to 27+6 weeks of gestation will be randomized at a 1:1 ratio and allocated to&#xD;
      either continue ASA until 36 weeks or to stop ASA treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of the study is to demonstrate that in patients considered to be at high&#xD;
      risk for PE (from the first-trimester screening) and with sFlt-1/PlGF ratio &lt;38, between 24+0&#xD;
      and 27+6 weeks, the incidence of preterm PE, after cessation of the treatment with ASA, will&#xD;
      not be superior to that of the control group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A phase III, multicentric, Randomized, open-label, parallel-group clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of preterm pre-eclampsia in both arms of the study (ASA vs no ASA).</measure>
    <time_frame>From 24+0 weeks of gestation onwards</time_frame>
    <description>Rate of pre-eclampsia &lt;37 weeks in pregnant women at high-risk for early-onset PE from the first-trimester screening and ratio sFlt-1/PlGF&lt;38 between 24-27+6 weeks of gestation in both arms of the study (ASA vs no ASA).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">878</enrollment>
  <condition>Pre-Eclampsia</condition>
  <arm_group>
    <arm_group_label>ASA-withdrawn group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASA treatment will be withdrawn if patients present an sFlt/PlGF &lt; 38 at 24+0-27+6 weeks of gestation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASA group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>ASA treatment will continue until 36 weeks of gestation if patients present an sFlt/PlGF ratio &lt; 38 at 24+0-27+6 weeks of gestation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASA-withdrawn group</intervention_name>
    <description>Patients whith sFlt/PlGF ratio &lt; 38 at 24+0-27+6 weeks will be randomized into two arms of the trial. Patients allocated in the experimental arm will stop the ASA treatment.</description>
    <arm_group_label>ASA-withdrawn group</arm_group_label>
    <other_name>sFlt y PlGF ratio less than 38.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients older than 18 years old&#xD;
&#xD;
          -  Gestational age between 24+0 and 27+6 weeks&#xD;
&#xD;
          -  Single pregnancy&#xD;
&#xD;
          -  High-risk for pre-eclampsia from the first-trimester screening for pre-eclampsia&#xD;
&#xD;
          -  ASA treatment started before or at 16+6 weeks of gestation&#xD;
&#xD;
          -  Maternal sFlt-1/PlGF ratio at 24+0-27+6 weeks of gestation&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multiple pregnancy&#xD;
&#xD;
          -  Dead and/or fetal polymalformation, including also any fetal genetical and/or&#xD;
             chromosomic disease.&#xD;
&#xD;
          -  Von Willebrand disease.&#xD;
&#xD;
          -  ASA intolerance and /or allergy&#xD;
&#xD;
          -  Peptic ulcer&#xD;
&#xD;
          -  ASA compliance &lt;50% before inclusion&#xD;
&#xD;
          -  Patients with misunderstanding or not able to understand the protocol, including also&#xD;
             any condition which could compromise the compliance of the protocol, according to the&#xD;
             investigator's opinion.&#xD;
&#xD;
          -  No signature of the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manel Mendoza Cobaleda, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vall d'Hebron Institut de Recerca (VHIR)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manel Mendoza Cobaleda, MD, PhD</last_name>
    <phone>+34 934 893 000</phone>
    <phone_ext>2702</phone_ext>
    <email>aro@vhir.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mercedes Villa</last_name>
    <phone>+34 934 893 000</phone>
    <phone_ext>2702</phone_ext>
    <email>mercedes.villa@vhir.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manel Mendoza, PhD</last_name>
      <phone>0034934893085</phone>
      <phone_ext>3264</phone_ext>
      <email>mmendoza@vhebron.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 25, 2018</study_first_submitted>
  <study_first_submitted_qc>November 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pre-eclampsia</keyword>
  <keyword>pregnant</keyword>
  <keyword>sFlt-1/PlGF ratio</keyword>
  <keyword>ASA treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Eclampsia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

